To investigate potential prognostic and predictive factors in patients with androgen-independent prostate cancer (AIPC) treated with docetaxel chemotherapy.
This analysis included 94 consecutive AIPC patients who were treated between March 2001 and May 2006 with biweekly docetaxel 45 mg/m2 (day 2) and estramustine 140 mg three dimes daily (days 1–3).
Prostate-specific antigen (PSA) responses were observed in 45 of 84 evaluable patients (53%), whereas objective responses were observed in 16 of 40 patients with measurable disease (40%). Median survival (OS) was 16.2 mo (95% confidence interval [CI], 12.9–19.4) and median time to PSA progression (TTP) 5.0 mo (95%CI, 3.6–7.1). OS was independently associated with pain score baseline PSA and weight loss. Patients with only extraosseous disease had higher PSA response rate (87% vs. 49%, p = 0.014) and superior TTP compared with patients with bone metastases with or without extraosseous disease (7.3 vs. 4.3 vs. 4 mo, p = 0.002). Concurrent bone and extraosseous metastases were associated with worse prognosis compared with each site alone (median OS: 12.3 vs.19 vs.18.3 mo, p = 0.007).
Among patients with AIPC treated with biweekly docetaxel and estramustine, baseline PSA >100, existence of pain, weight loss, and simultaneous extraosseous and bone disease were associated with worse prognosis. Extraosseous metastases seem to be more sensitive than bone disease to this chemotherapy.
Keywords: Chemotherapy, Docetaxel, Estramustine, Prognosis, Prostate cancer.
a Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece
b Amalia Fleming Hospital, Athens, Greece
c Erythros Stavros Hospital, Athens, Greece
d Polykliniki Athinon, Athens, Greece
e Department of Urology, University of Athens, School of Medicine, Athens, Greece
Corresponding author. 31 Komninon St, Haidari, Athens 124 62, Greece. Tel. +30 210 3381546; Fax: +30 210 3381511.
© 2007 European Association of Urology, Published by Elsevier B.V.